RE:RE:New Press Release - Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep The update on anal resukts, being three out of 4 branches of the Goblet study being positive, i# great news.
The PanCan re- evaluation?
confusing at best.
essentially no new trials until they reevaluate their programs.
Onc to proceed with phase 3 regardless. & still recieve tge $5 million for additional phase 2 arm.
big picture, I see a buyout from Roche a lot sooner than previously expected.
They have a combination that works in 3 out of 4 GI trials.
As I said the one update is great, the other?
more shoes to drop obviously.